2014 First-quarter revenue

2014 First-quarter revenue

Conference Call

Basel, 30 April 2014

This presentation contains certain forward-looking statements that reflect the current views of management. Such statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Straumann Group to differ materially from those expressed or implied in this presentation. Straumann is providing the information in this presentation as of this date and does not undertake any obligation to update any statements contained in it as a result of new information, future events or otherwise.

The availability and indications/claims of the products illustrated and mentioned in this presentation may vary according to country.

2014 YTD Highlights

Marco Gadola, CEO

Promising start to 2014; strongest quarter in

three years

REVENUE GROWTH1 _{MAIN CONTRIBUTOR}

CHF

180m

+6%

Europe

Performance reflects investments in growth markets, new products launches and soft baseline

Strongest quarter in 3 years. Continued improvement over 4 quarters.

Return to growth after 2 years of decline; contributes 41% of Q1 growth

BEST PERFORMERS MULTIBRAND STRATEGY ITI WORLD SYMPOSIUM

ROW & APAC

Biodenta, MegaGen

& botiss

Leading academic

event

Another strong quarter in LATAM and further improvements in Japan

Strategic investments/partnerships to strengthen presence in the value segment and in regenerative dentistry

Event used to promote new research and customer solutions

5



Leading academic event in oral

implantology



~4200 participants



Straumann Corporate Forum

attended by >2000 dental

professionals



Special promotions offered

Highly successful ITI World Symposium –

platform to promote new research and solutions

Regional and business review

Thomas Dressendörfer, CFO

7

Straumann, Nobel Biocare, Zimmer Dental, Biomet 3i, Dentsply Implants - based on company and SEC reports as well as management comments

4 consecutive quarters of solid growth

-12% -10% -8% -6% -4% -2% 0% 2% 4% 6% 8% 10%

Market for tooth replacement & restoration (leading implant companies) Straumann l.c. growth

5.2%

4.1% 8.3% 28.6%

Change in l.c.

Good growth across all regions

(3.1%) 2013 2014 6.0% in l.c. In CHF million 2.9% in CHF 174.8 ‐5.2 169.6 4.1 2.2 1.7 2.2 179.8 Revenues Q1 2013 FX Effect Revenues Q1 2013 @ FX 2014

Europe North America APAC ROW Revenues Q1

Europe & N. America – main growth contributors

56%

Return to growth in nearly all European countries

New implant price structure; customers upgrade to premium Roxolid implants

Spain and Nordics deliver strongest performance 4.1% (1.4%) (3.4%) 0.2% (7.7%) Q1 2014 Q4 2013 Q3 2013 Q2 2013 Q1 2013

Europe

North A

m

eric

a

_{Revenues 5% ahead of previous}

year

Mid-single-digit growth in the US and Canada

Strong demand for Roxolid and the Bone-Level implant range Revenue change (organic)

25% 9 5.2% 11.0% 9.1% 10.6% 2.1% Q1 2014 Q4 2013 Q3 2013 Q2 2013 Q1 2013 57%

Japan rebounds; LATAM dynamic

56%

 Good growth in APAC driven by Japan

 SLActive Tissue Level implant launch stimulates growth in largest Asian market

 Currency headwind (mainly JPY) cuts regional growth by 11% points 8.3% 16.3% 7.9% 0.9% -4.4% Q1 2014 Q4 2013 Q3 2013 Q2 2013 Q1 2013

A

sia

Pacific

Rest o

f

W

o

rld

_28.6% 1.8% 35.1% 4.1% -2.6% Q1 2014 Q4 2013 Q3 2013 Q2 2013 Q1 2013  Q1 revenue climbs 29% (l.c.)

 Strong performances in Mexico and Brazil

 Neodent also posts double-digit growth in Q1

 Erratic distributor ordering patterns

12%

5%

Implants

Solid growth in implants and prosthetics

Restorative

Regeneratives

11

Good strategic progress

Marco Gadola, CEO

13



Founded in 2002, MegaGen is one of Korea’s

fastest-growing dental implant companies



Straumann purchases 3%-interest-bearing convertible

bonds for a total of CHF 27 million



Capital injection will accelerate MegaGen’s expansion

plans



Option to convert bonds into shares in 2016 and to obtain

a majority stake in MegaGen



Foothold in the value segment of the Asia/Pacific region

Investment in MegaGen to drive expansion in

value implant segment in Asia



Exclusive rights for Straumann to distribute

botiss products in most Western/Central

European countries and the Americas



Botiss to distribute Emdogain

®

_{in Germany,}

parts of Eastern Europe and Middle East



Leading position for dental bone & tissue

regeneration in Europe; growing globally



Extensive range of proven biologic materials



Straumann to start selling in Europe in Q4;

other regions to follow in 2016/17, pending

clearances

Combining strengths with botiss to provide

complete regenerative solutions worldwide

A combination to eclipse the market leader

15 *US only

Straumann

botiss

Geistlich

Bone allografts

*

Bone xenografts

Bone synthetic grafts

Bone blocks

Custom bone blocks

Bone rings

Collagen cones

Fleeces & sponges

Membranes

Soft-tissue grafts

Biologics

Common platform for

technology & production

Separate-brand strategy to address premium and

value segments

Brazil

49%

2012 Germany

51%

2013 Taiwan Convertible bond 2014 Korea Convertible bond 2014 Spain

30%

2013 Canada

44%

2011 Germany Distribution & call option

2014

Germany

CADCAM

2014

2014 outlook helped by an

exciting roll-out program

New prosthetic components for fixed full-arch

restorations launched at ITI congress



Enhanced screw-retained prosthetic solution

especially for edentulous patients



New range of screw-retained implant

abutments offering increased flexibility



Low profile, different gingiva heights



0°, 17° and 30° angulations for challenging

situations where the posterior implant has to

be tilted

New

SR

abutments

Value-adding solutions to meet clinician and

patient needs

19 Bubble sizes illustrate market volume potential

Single tooth Multiple tooth Edentulous Ceramic implants Standard implant solution packages Simple edentulous solutions Fixed immediate edentulous solutions Smaller, less invasive implants Implants for narrow spaces

Esthetic, fast implant solutions with single crown / small bridge

Low High Cost-effective, open platform restoration Lev el of sophi sti cati o n Straumann ONE Ceramic implant Rox olid Straumann Variobase

 We expect the global implant market to develop positively in 2014 and our revenue to grow in the low-single-digit range (l.c.).

 After a promising Q1, we expect a softer Q2 given the later Easter break this year.

 We will continue to invest in dental growth markets and to extend the reach of our non-premium offering.

 Despite this, and thanks to the full impact of our cost-reduction measures last year, we expect to further expand operating income margin in 2014.

 In the mid-term, we aim to return to solid growth with further operating margin improvements.

Outlook for 2014 unchanged

Barring unforeseen circumstances

21

Questions & Answers

Calendar of upcoming events

2 0 1 4

30 April First quarter sales Audio webcast

05 May Investor meetings Milano

06 May Investor meetings Munich

11-12 June Vontobel Swiss Conference Interlaken/CH

13 June Deutsche Bank Swiss & German Conference Berlin

26 August Half-year 2014 results conference Basel HQ

23 October Third quarter sales Audio webcast

2 0 1 5

24 February Full-year 2014 results conference Basel HQ

23

Straumann’s currency exposure

Cost breakdown 20131

Revenue breakdown 2013

1_{These distribution charts represent the total net revenues and the total COGS as well as OPEX expenses in the various}

currencies. All numbers are rounded and based on 2013 figures.

Average exchange rates (rounded) FX sensitivity (+/- 10%) on...

FY 2013 YTD 2014 Revenue EBIT

EURCHF 1.23 1.23 +/- 25 million +/- 15 million

USDCHF 0.93 0.90 +/- 17 million +/- 7 million

JPYCHF 0.95 0.87 +/- 4 million +/- 2 million

Development of Straumann’s main exchange rates since 2012

23 EUR 40% CHF 12% USD / CAD / AUD 28% Other 20% EUR 21% CHF 45% USD / CAD / AUD 22% Other 12% 60 80 100 120 2012 2013 2014 USDCHF EURCHF JPYCHF

Your contacts

Fabian Hildbrand

Corporate Investor Relations

Tel. +41 (0)61 965 13 27

Email [email protected]

Mark Hill Thomas Konrad

Corporate Communications

Tel. +41 (0)61 965 13 21 Tel. +41 (0)61 965 15 46

International Headquarters Institut Straumann AG Peter Merian-Weg 12 CH-4002 Basel, Switzerland Phone +41(0)61 965 11 11 Fax +41(0)61 965 10 01 www.straumann.com